| Cover | 12 Months Ended |
| Dec. 31, 2022 | |
| Document Information [Line Items] | |
| Document Type | DEF 14A |
| Amendment Flag | false |
| Entity Information [Line Items] | |
| Entity Registrant Name | Fate Therapeutics, Inc. |
| Entity Central Index Key | 0001434316 |
| Pay vs Performance Disclosure - USD ($) | 12 Months Ended | ||
| Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Pay vs Performance Disclosure [Table] | |||
| Pay vs Performance [Table Text Block] | Pay versus Performance Year Summary ($) Compensation ($) Average Non-PEO ($) Average Non-PEO ($) Value of Initial Fixed $100 Net (in thousands) ($) Total ($) Peer Group ($) (a) (b) (c) (d) (e) (f) (g) (h) 2022 8,145,000 (12,366,963 ) 3,179,591 (3,125,934 ) 51.56 111.27 (281,721 ) 2021 11,728,617 (11,644,474 ) 6,839,065 (2,075,456 ) 298.98 124.89 (212,151 ) 2020 5,600,167 78,596,425 3,265,217 22,797,818 464,64 125.69 (173,387 ) The Company does not use any financial performance measures in its compensation program and as a result, does not have a Company-Selected Measure. (1) The dollar amounts reported in column (b) are the amounts of total compensation reported for J. Scott Wolchko for each corresponding year in the “Total” column of the Summary Compensation Table. Refer to “Compensation of Executive Officers—Summary Compensation Table”. (2) The dollar amounts reported in column (c) represent the amount of “compensation actually paid” to Mr. Wolchko, as computed in accordance with Item 402(v) of Regulation S-K. S-K, Year Reported Summary ($) Reported Value of ($) Equity Award ($) Compensation ($) 2022 8,145,000 (7,500,000 ) (13,011,963 ) (12,366,963 ) 2021 11,728,617 (10,752,617 ) (12,620,474 ) (11,644,474 ) 2020 5,600,167 (4,673,917 ) 77,670,175 78,596,425 (a) The grant date fair value of equity awards represents the total of the amounts reported in the “Option Awards” columns in the Summary Compensation Table for the applicable year. (b) The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows: Year Year End Fair Awards ($) Year over Year Outstanding ($) Fair Value ($) Year over ($) Fair Value at ($) Value of ($) Total Equity 2022 1,457,114 (9,384,451 ) 1,093,557 (6,178,183 ) — — (13,011,963 ) 2021 3,066,436 (14,190,573 ) 200,247 (1,696,584 ) — — (12,620,474 ) 2020 19,255,034 46,371,817 1,972,225 10,071,099 — — 77,670,175 47 (3) The dollar amounts reported in column (d) represent the average of the amounts reported for our company’s named executive officers as a group (excluding Mr. Wolchko) in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the named executive officers (excluding Mr. Wolchko) included for purposes of calculating the average amounts in each applicable year are as follows: Year Non-PEO 2022 Edward Dulac, Bahram Valamehr, Cindy Tahl, Yu-Waye Chu, Mark Plavsic 2021 Edward Dulac, Bahram Valamehr, Cindy Tahl, Yu-Waye Chu, Mark Plavsic 2020 Edward Dulac, Bahram Valamehr, Cindy Tahl, Daniel Shoemaker (4) The dollar amounts reported in column (e) represent the average amount of “compensation actually paid” to the named executive officers as a group (excluding Mr. Wolchko), as computed in accordance with Item 402(v) of Regulation S-K. S-K, Year Reported Summary Non-PEO ($) Reported Value of ($) Equity Award ($) Compensation Actually Non- ($) 2022 3,179,591 (2,702,751 ) (3,602,774 ) (3,125,934 ) 2021 6,839,065 (6,266,227 ) (2,648,294 ) (2,075,456 ) 2020 3,265,217 (2,707,405 ) 22,240,006 22,797,818 (a) The grant date fair value of equity awards represents the total of the amounts reported in the “Option Awards” columns in the Summary Compensation Table for the applicable year. (b) The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows: Year Year End Fair ($) Year over Year ($) Fair Value ($) Year over ($) Fair Value at ($) Value of ($) Total Equity 2022 603,183 (2,864,205 ) 200,428 (1,542,179 ) — — (3,602,774 ) 2021 1,628,810 (3,208,590 ) 66,515 (1,135,029 ) — — (2,648,294 ) 2020 9,655,060 9,152,818 575,915 2,856,213 — — 22,240,006 (5) The calculation of Cumulative TSR assumes that $100 was invested in our common stock as of the market close on December 31, 2019. (6) For the relevant fiscal year, represents the cumulative TSR of the NASDAQ Biotechnology Index. The calculation of Cumulative TSR assumes that $100 was invested in the comparative index as of the market close on December 31, 2019. (7) The dollar amounts reported represent the amount of net income (loss) reflected in our consolidated audited financial statements for the applicable year. | ||
| Named Executive Officers, Footnote [Text Block] | The dollar amounts reported in column (d) represent the average of the amounts reported for our company’s named executive officers as a group (excluding Mr. Wolchko) in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the named executive officers (excluding Mr. Wolchko) included for purposes of calculating the average amounts in each applicable year are as follows: Year Non-PEO 2022 Edward Dulac, Bahram Valamehr, Cindy Tahl, Yu-Waye Chu, Mark Plavsic 2021 Edward Dulac, Bahram Valamehr, Cindy Tahl, Yu-Waye Chu, Mark Plavsic 2020 Edward Dulac, Bahram Valamehr, Cindy Tahl, Daniel Shoemaker | ||
| Peer Group Issuers, Footnote [Text Block] | For the relevant fiscal year, represents the cumulative TSR of the NASDAQ Biotechnology Index. The calculation of Cumulative TSR assumes that $100 was invested in the comparative index as of the market close on December 31, 2019 | ||
| PEO Total Compensation Amount | $ 8,145,000 | $ 11,728,617 | $ 5,600,167 |
| PEO Actually Paid Compensation Amount | $ (12,366,963) | (11,644,474) | 78,596,425 |
| Adjustment To PEO Compensation, Footnote [Text Block] | The dollar amounts reported in column (c) represent the amount of “compensation actually paid” to Mr. Wolchko, as computed in accordance with Item 402(v) of Regulation S-K. S-K, Year Reported Summary ($) Reported Value of ($) Equity Award ($) Compensation ($) 2022 8,145,000 (7,500,000 ) (13,011,963 ) (12,366,963 ) 2021 11,728,617 (10,752,617 ) (12,620,474 ) (11,644,474 ) 2020 5,600,167 (4,673,917 ) 77,670,175 78,596,425 (a) The grant date fair value of equity awards represents the total of the amounts reported in the “Option Awards” columns in the Summary Compensation Table for the applicable year. (b) The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows: Year Year End Fair Awards ($) Year over Year Outstanding ($) Fair Value ($) Year over ($) Fair Value at ($) Value of ($) Total Equity 2022 1,457,114 (9,384,451 ) 1,093,557 (6,178,183 ) — — (13,011,963 ) 2021 3,066,436 (14,190,573 ) 200,247 (1,696,584 ) — — (12,620,474 ) 2020 19,255,034 46,371,817 1,972,225 10,071,099 — — 77,670,175 | ||
| Non-PEO NEO Average Total Compensation Amount | $ 3,179,591 | 6,839,065 | 3,265,217 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ (3,125,934) | (2,075,456) | 22,797,818 |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | The dollar amounts reported in column (e) represent the average amount of “compensation actually paid” to the named executive officers as a group (excluding Mr. Wolchko), as computed in accordance with Item 402(v) of Regulation S-K. S-K, Year Reported Summary Non-PEO ($) Reported Value of ($) Equity Award ($) Compensation Actually Non- ($) 2022 3,179,591 (2,702,751 ) (3,602,774 ) (3,125,934 ) 2021 6,839,065 (6,266,227 ) (2,648,294 ) (2,075,456 ) 2020 3,265,217 (2,707,405 ) 22,240,006 22,797,818 (a) The grant date fair value of equity awards represents the total of the amounts reported in the “Option Awards” columns in the Summary Compensation Table for the applicable year. (b) The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows: Year Year End Fair ($) Year over Year ($) Fair Value ($) Year over ($) Fair Value at ($) Value of ($) Total Equity 2022 603,183 (2,864,205 ) 200,428 (1,542,179 ) — — (3,602,774 ) 2021 1,628,810 (3,208,590 ) 66,515 (1,135,029 ) — — (2,648,294 ) 2020 9,655,060 9,152,818 575,915 2,856,213 — — 22,240,006 | ||
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | Description of Relationship Between PEO and Non-PEO The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO | ||
| Compensation Actually Paid vs. Net Income [Text Block] | Description of Relationship and Non-PEO The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO | ||
| Total Shareholder Return Vs Peer Group [Text Block] | Description of Relationship Between Company TSR and Peer Group TSR The following chart compares our cumulative TSR over the three most recently completed fiscal years to that of the NASDAQ Biotechnology Index over the same period. | ||
| Total Shareholder Return Amount | $ 51.56 | 298.98 | 46,464 |
| Peer Group Total Shareholder Return Amount | 111.27 | 124.89 | 125.69 |
| Net Income (Loss) | $ (281,721,000) | (212,151,000) | (173,387,000) |
| PEO Name | J. Scott Wolchko | ||
| PEO [Member] | Value Of Equity Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ (7,500,000) | (10,752,617) | (4,673,917) |
| PEO [Member] | Total Equity Award Adjustments [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (13,011,963) | (12,620,474) | 77,670,175 |
| PEO [Member] | Year End Fair Value Of Outstanding And Unvested Equity Awards Granted In The Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 1,457,114 | 3,066,436 | 19,255,034 |
| PEO [Member] | Year Over Year Change In Fair Value Of Outstanding And Unvested Equity Awards Granted In Prior Years [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (9,384,451) | (14,190,573) | 46,371,817 |
| PEO [Member] | Fair Value As Of Vesting Date Of Equity Awards Granted And Vested In The Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 1,093,557 | 200,247 | 1,972,225 |
| PEO [Member] | Year Over Year Change In Fair Value Of Equity Awards Granted In Prior Years That Vested In The Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (6,178,183) | (1,696,584) | 10,071,099 |
| Non-PEO NEO [Member] | Value Of Equity Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (2,702,751) | (6,266,227) | (2,707,405) |
| Non-PEO NEO [Member] | Total Equity Award Adjustments [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (3,602,774) | (2,648,294) | 22,240,006 |
| Non-PEO NEO [Member] | Year End Fair Value Of Outstanding And Unvested Equity Awards Granted In The Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 603,183 | 1,628,810 | 9,655,060 |
| Non-PEO NEO [Member] | Year Over Year Change In Fair Value Of Outstanding And Unvested Equity Awards Granted In Prior Years [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (2,864,205) | (3,208,590) | 9,152,818 |
| Non-PEO NEO [Member] | Fair Value As Of Vesting Date Of Equity Awards Granted And Vested In The Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 200,428 | 66,515 | 575,915 |
| Non-PEO NEO [Member] | Year Over Year Change In Fair Value Of Equity Awards Granted In Prior Years That Vested In The Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ (1,542,179) | $ (1,135,029) | $ 2,856,213 |
